Dr. Sven Kili is a respected KOL in healthcare and biotechnology, with over 20 years of experience. He trained as a Trauma and Orthopaedic surgeon in the NHS, where he gained valuable insights into patient care. Transitioning to Cell and Gene Therapies (CGT), Sven played key roles in leading the development, approval and commercialization of both the first combined cell therapy and later the first ex-vivo gene therapy. With expertise across all stages of CGT development, he has built companies and teams in both large pharma/ biotech and startups.

Sven is a partner at Saisei Ventures, a boutique therapeutic venture investment firm focussed on creating and growing innovative biotech companies, including with a focus on the Japanese CGT ecosystem and championing international expansion. His past roles included Chief Development Officer for CCRM & OmniaBio, CEO of a Swiss start-up developing multiplex engineered immune cell therapies, Development head for Cell & Gene Therapies, GSK and Medical Lead for Genzyme Regen Med business unit, in addition to his consulting business. His most recent endeavour is as a founder of AT3 (Advanced Therapies Think Tank) creating monthly in-depth online panel discussions for the CGT ecosystem. 

Sven actively contributes to industry boards and committees, including the BIA CGTAC, Innovation Hubs for Gene Therapy, BHF, ISCT, and ARM. Sven holds a visiting chair at UCL (University College London), where he lectures & chairs the steering committee for the post-grad degree in Cell & Gene Therapy manufacturing and commercialisation. His dedication to advancing regenerative medicine and CGT is reflected in his multifaceted roles and ongoing efforts to shape the future of healthcare through innovation and strategic collaboration.